Lenvatinib Mesylate Intermediate CAS 205448-65-3 Purity >98.0% (HPLC) Factory

Short Description:

Chemical Name: Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate

CAS: 205448-65-3

Purity: >98.0% (HPLC)

Appearance: Off-White to Yellowish Powder

Intermediate of Lenvatinib Mesylate CAS 857890-39-2

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Ruifu Chemical Supply Lenvatinib Mesylate Intermediates With High Purity
Lenvatinib Mesylate CAS 857890-39-2
4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
Desquinolinyl Lenvatinib; 1-(2-Chloro-4-Hydroxyphenyl)-3-Cyclopropylurea CAS 796848-79-8
Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate CAS 205448-65-3
Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5-(Methoxymethylene)-2,2-Dimethyl-1,3-Dioxane-4,6-Dione CAS 15568-85-1
4-Amino-3-Chlorophenol CAS 17609-80-2
4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4

Chemical Properties:

Chemical Name	Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate
Synonyms	1,4-Dihydro-7-Methoxy-4-Oxo-6-Quinolinecarboxylic Acid Methyl Ester; 7-Methoxy-4-Oxo-1,4-Dihydro-Quinoline-6-Carboxylic Acid Methyl Ester; Lenvatinib Intermediate 3
CAS Number	205448-65-3
CAT Number	RF-PI1973
Stock Status	In Stock, Production Capacity 50 MT/Year
Molecular Formula	C12H11NO4
Molecular Weight	233.22
Boiling Point	421.0±45.0℃
Density	1.267±0.060 g/cm3
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	Off-White to Yellowish Powder
Purity / Analysis Method	>98.0% (HPLC)
Loss on Drying	<1.00%
Residue on Ignition	<0.50%
Total Impurities	<2.00%
H-NMR	Conforms to Structure
Test Standard	Enterprise Standard
Usage	Pharmaceutical Intermediates

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture

Advantages:

FAQ:

Application:

Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate (CAS: 205448-65-3) is an intermediate of Lenvatinib Mesylate (CAS: 857890-39-2). Lenvatinib, sold under the brand name Lenvima among others, is an anti-cancer medication for the treatment of certain kinds of thyroid cancer and for other cancers as well. It was developed by Eisai Co. and acts as a multiple kinase inhibitor against the VEGFR1, VEGFR2 and VEGFR3 kinases. Lenvatinib is approved (since 2015) for the treatment of differentiated thyroid cancer that is either locally recurrent or metastatic, progressive, and did not respond to treatment with radioactive iodine (radioiodine). In May 2016, the U.S. Food and Drug Administration (FDA) approved it (in combination with everolimus) for the treatment of advanced renal cell carcinoma following one prior anti-angiogenic therapy. The drug is also approved in the US and in the European Union for hepatocellular carcinoma that cannot be removed surgically in patients who have not received cancer therapy by mouth or injection.